New product launch Leverage the recent DPNCheck 2.0 and SENSUS Pain Management System launches to target клиник physicians and pain specialists seeking updated, non-invasive diagnostic and treatment tools for peripheral neuropathy and chronic neuropathic pain.

Acquisition spark With electroCore's acquisition of NeuroMetrix, there is a strategic opportunity to cross-sell Quell platform services and cloud-enabled wearables to electroCore’s existing customer base while highlighting integrated neurotechnology solutions.

Fibromyalgia angle The Pathfinder program for Quell Fibromyalgia provides a foothold to approach clinics treating fibromyalgia, offering a wearable neuromodulation option as a non-pharmacologic therapy to expand pain management offerings.

Global commercialization NeuroMetrix focuses on global commercialization of non-invasive devices; align sales efforts with international opportunities for DPNCheck, ADVANCE and Quell across markets with growing demand for point-of-care diagnostics and wearable pain therapies.

Strategic partnerships Target collaborations with clinics, hospitals, and payer partners to expand reimbursement-ready solutions, emphasizing automated nerve conduction testing, automated in-office studies, and wearable neuromodulation as comprehensive diagnostic and treatment platforms.